ABSI Absci Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1672688 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-47.2%
TTM net income YoY-9.7%
TTM EPS YoY13.2%
Revenue 3-yr CAGR-40.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,812.3%
Net margin-8,451.3%
FCF margin-7,562.7%
EBITDA margin-8,076.6%
Returns
ROE-58.6%
ROA-51.9%
ROIC (approx.)-53.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio9.64x
Interest coverage-2,569.39x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue-4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $304,000 | $318,000 | $215,000 | $650,000 | $378,000 | $593,000 | $1.18M | $665,000 |
| R&D expense | $23.57M | $22.62M | $19.27M | $25.35M | $19.25M | $20.46M | $16.36M | $18.38M |
| SG&A expense | $9.04M | $9.16M | $9.06M | $8.62M | $8.44M | $8.53M | $9.47M | $8.83M |
| Operating income | -$34.99M | -$34.16M | -$30.85M | -$31.04M | -$30.15M | -$31.39M | -$27.73M | -$29.77M |
| Interest expense | $2,000 | $2,000 | $18,000 | $29,000 | $45,000 | $56,000 | $79,000 | $109,000 |
| Pretax income | -$33.28M | -$33.17M | -$29.58M | -$29.72M | -$28.60M | -$30.44M | -$26.35M | -$28.96M |
| Income tax | $18,000 | $40,000 | $18,000 | -$162,000 | $104,000 | $131,000 | -$4,000 | $21,000 |
| Net income | -$33.30M | -$33.21M | -$29.60M | -$29.56M | -$28.71M | -$30.57M | -$26.35M | -$28.98M |
| EBITDA | -$32.31M | -$31.46M | -$28.12M | -$28.21M | -$27.31M | -$28.39M | -$24.66M | -$26.54M |
| EPS (basic) | -0.19 | -0.21 | -0.19 | — | -0.20 | -0.24 | -0.21 | — |
| EPS (diluted) | -0.19 | -0.21 | -0.19 | — | -0.20 | -0.24 | -0.21 | — |
| Weighted avg. shares (diluted) | 171.80M | 157.47M | 152.96M | — | 143.77M | 127.59M | 124.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.36M | $107.86M | $8.63M | $20.02M | $26.87M | $55.29M | $64.12M | $58.21M |
| Short-term investments | $160.37M | $93.28M | $117.08M | $124.27M | $143.00M | — | — | $71.21M |
| Receivables | — | — | — | — | $1.00M | $700,000 | $1.38M | $0 |
| Current assets | $181.89M | $208.27M | $131.97M | $149.57M | $174.99M | $137.40M | $155.98M | $133.83M |
| PP&E, net | $14.76M | $16.72M | $18.78M | $20.86M | $23.02M | $24.06M | $27.03M | $29.17M |
| Intangibles | $39.33M | $40.05M | $40.77M | $41.51M | $42.36M | $43.20M | $44.04M | $44.88M |
| Total assets | $239.57M | $268.92M | $195.59M | $216.30M | $244.99M | $209.89M | $232.45M | $213.61M |
| Current liabilities | $18.86M | $19.60M | $20.03M | $22.77M | $29.71M | $31.32M | $27.28M | $28.66M |
| Long-term debt | — | — | — | — | — | — | — | $3.99M |
| Total debt | — | — | — | — | — | — | — | $3.99M |
| Total liabilities | $20.90M | $22.79M | $23.62M | $26.85M | $34.65M | $36.52M | $33.65M | $34.48M |
| Shareholders' equity | $218.68M | $246.13M | $171.97M | $189.45M | $210.34M | $173.37M | $198.80M | $179.13M |
| Net debt | — | — | — | — | — | — | — | -$54.22M |
| Shares outstanding | — | — | — | — | — | — | — | 115.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$29.47M | -$27.56M | -$26.31M | -$29.18M | -$25.03M | -$16.87M | -$21.84M | -$16.96M |
| Capital expenditure | $9,000 | $1,000 | $30,000 | -$103,000 | $962,000 | $223,000 | $25,000 | $23,000 |
| Free cash flow | -$29.48M | -$27.57M | -$26.34M | -$29.08M | -$25.99M | -$17.10M | -$21.86M | -$16.99M |
| Investing cash flow | -$67.05M | $24.07M | $7.36M | $19.55M | -$63.70M | $9.04M | -$15.04M | $19.04M |
| Financing cash flow | $2.02M | $102.73M | $7.56M | $3.84M | $60.32M | -$1.00M | $42.79M | $986,000 |
| Depreciation & amortization | $2.69M | $2.70M | $2.73M | $2.83M | $2.84M | $3.00M | $3.07M | $3.23M |
| Stock-based compensation | $4.47M | $5.25M | $4.38M | $4.26M | $4.40M | $4.75M | $4.91M | $5.07M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.